Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe : a CP-North registry study

Show full item record



Permalink

http://hdl.handle.net/10138/334523

Citation

Hägglund , G , Hollung , S J , Ahonen , M , Andersen , G L , Eggertsdottir , G , Gaston , M S , Jahnsen , R , Jeglinsky-Kankainen , I , Nordbye-Nielsen , K , Tresoldi , I & Alriksson-Schmidt , A 2021 , ' Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe : a CP-North registry study ' , BMC Neurology , vol. 21 , no. 1 , 276 . https://doi.org/10.1186/s12883-021-02289-3

Title: Treatment of spasticity in children and adolescents with cerebral palsy in Northern Europe : a CP-North registry study
Author: Hägglund, Gunnar; Hollung, Sandra Julsen; Ahonen, Matti; Andersen, Guro L.; Eggertsdottir, Guobjorg; Gaston, Mark S.; Jahnsen, Reidun; Jeglinsky-Kankainen, Ira; Nordbye-Nielsen, Kirsten; Tresoldi, Ilaria; Alriksson-Schmidt, Ann
Other contributor: University of Helsinki, HUS Children and Adolescents

Date: 2021-07-12
Language: eng
Number of pages: 12
Belongs to series: BMC Neurology
ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-021-02289-3
URI: http://hdl.handle.net/10138/334523
Abstract: BackgroundSpasticity is present in more than 80% of the population with cerebral palsy (CP). The aim of this study was to describe and compare the use of three spasticity reducing methods; Botulinum toxin-A therapy (BTX-A), Selective dorsal rhizotomy (SDR) and Intrathecal baclofen therapy (ITB) among children and adolescents with CP in six northern European countries.MethodsThis registry-based study included population-based data in children and adolescents with CP born 2002 to 2017 and recorded in the follow-up programs for CP in Sweden, Norway, Denmark, Iceland and Scotland, and a defined cohort in Finland.ResultsA total of 8,817 individuals were included. The proportion of individuals treated with SDR and ITB was significantly different between the countries. SDR treatment ranged from 0% ( Finland and Iceland) to 3.4% (Scotland) and ITB treatment from 2.2% (Sweden) to 3.7% (Denmark and Scotland). BTX-A treatment in the lower extremities reported 2017-2018 ranged from 8.6% in Denmark to 20% in Norway (p
Subject: Spasticity
Cerebral palsy
Treatment
Baclofen
Selective dorsal rhizotomy
Botulinum toxin
SELECTIVE POSTERIOR RHIZOTOMY
GROSS MOTOR FUNCTION
FOLLOW-UP
BACLOFEN
BORN
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Treatment_of_spasticity_in_children_and...pdf 2.920Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record